OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) insider Gregory A. Odle sold 5,359 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $133,224.74. Following the transaction, the insider now directly owns 148,788 shares in the company, valued at $3,698,869.68. This trade represents a 3.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
OrthoPediatrics Stock Performance
OrthoPediatrics stock opened at $25.54 on Friday. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19. The firm has a 50-day moving average of $24.84 and a 200-day moving average of $25.53. The firm has a market cap of $620.29 million, a P/E ratio of -20.76 and a beta of 1.22. OrthoPediatrics Corp. has a 1-year low of $21.02 and a 1-year high of $35.99.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The company had revenue of $52.67 million during the quarter, compared to analyst estimates of $51.16 million. During the same period in the prior year, the business posted ($0.23) earnings per share. Sell-side analysts expect that OrthoPediatrics Corp. will post -0.93 EPS for the current year.
Institutional Trading of OrthoPediatrics
Analysts Set New Price Targets
A number of research analysts have recently issued reports on KIDS shares. Truist Financial reduced their price objective on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $42.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, March 5th. Finally, Stifel Nicolaus reduced their price objective on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th.
Read Our Latest Stock Report on KIDS
OrthoPediatrics Company Profile
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
Featured Articles
- Five stocks we like better than OrthoPediatrics
- What is a Stock Market Index and How Do You Use Them?
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Business Services Stocks Investing
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- What Does Downgrade Mean in Investing?
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.